This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus, or RSV for infants. It is under development by AstraZeneca and Sanofi. Nirsevimab is designed to bind to the fusion protein on the surface of the RSV virus. The most common side effects reported for nirsevimab are rash, pyrexia (fever) and injection site reactions (such as redness, swelling and pain where the injection is given). Nirsevimab was approved for medical use in the European Union in November 2022.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:chEMBL |
|
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:kegg |
|
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chembl |
|
| dbp:drugbank |
|
| dbp:h |
|
| dbp:kegg |
|
| dbp:legalEu |
|
| dbp:mabType |
|
| dbp:n |
|
| dbp:o |
|
| dbp:pubchemsubstance |
|
| dbp:routesOfAdministration | |
| dbp:s |
|
| dbp:source |
|
| dbp:synonyms |
|
| dbp:target |
|
| dbp:tradename |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |